Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.41 |
| ▸ | MEN1 | O00255 | 6/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | DHODH | Q02127 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7835848 | 1.00 | PKM (0.48) | PKMALDH1A1NPSR1MAPTMAPK1 | |
| SCHEMBL12458210 | 0.85 | NPC1 (0.40) | ALDH1A1MAPTHTTCYP1A2CYP2D6 | |
| SCHEMBL12646742 | 0.85 | ALDH1A1 (0.47) | PKMALDH1A1NPSR1MAPTMAPK1 | |
| SCHEMBL7836695 | 0.84 | ALDH1A1 (0.49) | PKMALDH1A1NPSR1MAPTMAPK1 | |
| SCHEMBL7836692 | 0.84 | ALDH1A1 (0.49) | PKMALDH1A1NPSR1MAPTMAPK1 | |
| SCHEMBL10979799 | 0.82 | ALDH1A1 (0.65) | PKMALDH1A1NPSR1MAPTMAPK1 | |
| SCHEMBL7823361 | 0.80 | ALDH1A1 (0.45) | PKMALDH1A1NPSR1MAPTMAPK1 | |
| SCHEMBL7823363 | 0.80 | ALDH1A1 (0.45) | PKMALDH1A1NPSR1MAPTMAPK1 | |
| SCHEMBL25691621 | 0.76 | CYP3A4 (0.46) | ALDH1A1NPSR1MAPTMAPK1CYP1A2 | |
| SCHEMBL18949530 | 0.76 | MEN1 (0.41) | ALDH1A1NPSR1MAPTMAPK1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9676774-B2 | Compounds and compositions for treatment of cancer | SUNESIS PHARMACEUTICALS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20170101404-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF CANCER | SUNESIS PHARMACEUTICALS INC (US) | 2017-04-13 | — | — | US | disclosed |
| US-8765954-B2 | 1,8-naphthyridine compounds for the treatment of cancer | SUNESIS PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20120245198-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF CANCER | SUNESIS PHARMACEUTICALS INC. | 2012-09-27 | — | — | US | disclosed |
| US-8124773-B2 | 1,8-naphthyridine compounds for the treatment of cancer | SUNESIS PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100029708-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF CANCER | SUNESIS PHARMACEUTICALS, INC. | 2010-02-04 | — | — | US | disclosed |
| EP-0787726-B1 | NOVEL COMPOUND, PROCESS FOR PRODUCING THE SAME, AND ANTITUMOR AGENT | DAINIPPON PHARMACEUTICAL CO (JP) | 2001-11-28 | — | — | EP | disclosed |
| US-5817669-A | A COMPOUND CONTAINING 1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1998-10-06 | — | — | US | disclosed |
| EP-0787726-A1 | NOVEL COMPOUND, PROCESS FOR PRODUCING THE SAME, AND ANTITUMOR AGENT | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1997-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245198-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF CANCER | NTPCR, NNMT, NES | PKM 1916/4885ALDH1A1 2487/4885NPSR1 558/4885 |
| US-20170101404-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF CANCER | NTPCR, NNMT, NES | PKM 1916/4885ALDH1A1 2487/4885NPSR1 558/4885 |
| US-20100029708-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF CANCER | NTPCR, NNMT, NES | PKM 1916/4885ALDH1A1 2487/4885NPSR1 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.